Related Experiment Video
Updated: Jul 14, 2025
Protein Engineering by Yeast Surface Display
Published on: November 29, 2024
Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface
Arman Hosseini1, Sachin Kumar1, Kyle Hedin1
1Department of Chemical and Materials Engineering, University of Nevada, Reno, NV, USA.
Abstract:
Overexpression of specific matrix metalloproteinases (MMPs) has a key role in development of several diseases, such as cancer, neurological disorders, and cardiovascular diseases due to their critical role in degradation and remodeling of the extracellular matrix (ECM). Tissue inhibitors of metalloproteinases (TIMPs), a family of four in humans, are endogenous inhibitors of MMPs. TIMPs have a high level of sequence and structure homology, with a broad range of binding and inhibition to the family of MMPs. It is important to identify the key motifs of TIMPs responsible for inhibition of MMPs to develop efficient therapeutics targeting specific MMPs. We used DNA shuffling between the human TIMP family to generate a minimal TIMP hybrid library in yeast to identify the dominant minimal MMP inhibitory regions. The minimal TIMP variants screened toward MMP-3 and MMP-9 using fluorescent-activated cell sorting (FACS). Interestingly, several minimal TIMP variants selected after screening toward MMP-3cd or MMP-9cd, with lengths as short as 20 amino acids, maintained or improved binding to MMP-3 and MMP-9. The TIMP-MMP binding dissociation constant (KD ), in the nM range, and MMP inhibition constants (Ki ), in the pM range, of these minimal TIMP variants were similar to the N-terminal domain of TIMP-1 on the yeast surface and in solution indicating the potency of these minimal variants as MMP inhibitors. We further used molecular modeling simulation, and molecular docking of the minimal TIMP variants in complex with MMP-3cd to understand the binding and inhibition mechanism of these variants.
Insights
Researchers engineered minimal tissue inhibitor of metalloproteinases (TIMP) variants, as short as 20 amino acids, that effectively inhibit matrix metalloproteinases (MMPs). These potent MMP inhibitors show promise for developing targeted therapeutics for diseases like cancer.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Matrix metalloproteinases (MMPs) are crucial in extracellular matrix remodeling and implicated in diseases like cancer and cardiovascular disorders.
- Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of MMPs, offering therapeutic potential.
- Identifying key inhibitory motifs within TIMPs is essential for developing targeted MMP therapeutics.
Purpose of the Study:
- To generate and identify minimal MMP inhibitory regions from human TIMP variants.
- To characterize the binding affinity and inhibitory potency of these minimal TIMP variants against specific MMPs.
- To elucidate the binding and inhibition mechanisms of minimal TIMP variants using computational methods.
Main Methods:
- DNA shuffling of human TIMP family genes to create a minimal TIMP hybrid library in yeast.
- Fluorescent-activated cell sorting (FACS) for screening minimal TIMP variants against MMP-3 and MMP-9.
- Determination of binding dissociation constants (KD) and inhibition constants (Ki) in vitro.
- Molecular modeling and docking simulations to analyze TIMP-MMP interactions.
Main Results:
- Several minimal TIMP variants, as short as 20 amino acids, demonstrated maintained or enhanced binding to MMP-3 and MMP-9.
- These minimal variants exhibited potent inhibition with dissociation constants (KD) in the nanomolar range and inhibition constants (Ki) in the picomolar range.
- Computational analyses provided insights into the binding and inhibition mechanisms of the minimal TIMP variants.
Conclusions:
- Minimal TIMP variants can retain or improve MMP inhibitory function, offering a basis for novel therapeutic strategies.
- These findings highlight the potential of engineered minimal TIMP domains as potent and specific inhibitors for MMP-related diseases.
- The study provides a foundation for the rational design of targeted therapeutics by understanding essential TIMP inhibitory motifs.
